KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Patient-Reported Outcomes in the Phase III OASIS-HAE Study of Donidalorsen for Hereditary Angioedema.

Marc A Riedl, Aaron Yarlas, Laura Bordone, Sabrina Treadwell, Sophie Wang, Kenneth B Newman, Danny M Cohn

Allergy 80(8) 2361-2368

PMID40251904
PMCIDPMC12368753
DOI10.1111/all.16563
发表日期2025-04-19
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:生活质量量表图;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。
摘要

摘要

BACKGROUND: Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, frequently severe swelling that negatively impacts patients' quality of life (QoL). In the phase III OASIS-HAE study (NCT05139810), donidalorsen reduced HAE attack rate, increased disease control, and improved QoL. Here, we report further analysis of donidalorsen's impact on QoL and other patient-reported outcomes (PROs). METHODS: This double-blind, placebo-controlled study randomized patients with HAE to donidalorsen 80 mg or placebo once every 4 (Q4W) or 8 weeks (Q8W) over 24 weeks. PROs included Angioedema (AE)-QoL Questionnaire, Angioedema Control Test (AECT), Patient Global Impression of Severity (PGIS), and Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions (WPAI+CIQ). RESULTS: Ninety patients received donidalorsen Q4W (n = 45), donidalorsen Q8W (n = 23), or placebo (n = 22). A larger percentage of the donidalorsen Q4W group (88%) achieved clinically meaningful improvement (≥ 6-point reduction) in AE-QoL total score vs. placebo (45%). Both donidalorsen groups reported larger least-squares mean (LSM) changes from baseline to week 24 vs. placebo in AE-QoL functioning (difference: Q4W, -24.5; Q8W, -16.1), fears/shame (Q4W, -23.9; Q8W, -20.1), and nutrition (Q4W, -15.7; Q8W, -10.7) domains. Donidalorsen improved AECT scores vs. placebo (difference: Q4W, 6.0; Q8W, 4.1). A greater proportion of the donidalorsen Q4W group reported decreased disease severity vs. the placebo group (PGIS; 82% vs. 44%). Donidalorsen Q4W showed benefits vs. placebo in the presenteeism, overall work/school impairment, and activity impairment domains of the WPAI+CIQ. CONCLUSIONS: Donidalorsen significantly improved QoL and other PROs vs. placebo in patients with HAE.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Change in AE‐QoL domain scores from baseline to week 24. * p < 0.05; ** p < 0.01; *** p < 0.001. AE‐QoL, Angioedema Quality of Life Questionnaire; LSM, least‐squares mean; Q4W, every 4 weeks; Q8W, every 8 weeks; SC, subcutaneous; SEM, standard error of the mean.
非 KM Figure
FIGURE 2FIGURE 2 AECT total score by study week. Observed means, not modeled least‐squares means, are presented here because continuous AECT scores were only modeled at baseline and week 24. The dashed line represents the value at which patients' disease is considered well controlled (AECT = 10). AECT, Angioedema Control Test; Q4W, every 4 weeks; Q8W, every 8 weeks; SC, subcutaneous; SEM, standard error of the mean.
非 KM Figure
FIGURE 3FIGURE 3 Percentage of patients rating disease severity from none to very severe on the PGIS at week 24. PGIS, Patient Global Impression of Severity; Q4W, every 4 weeks; Q8W, every 8 weeks; SC, subcutaneous.
非 KM Figure
FIGURE 4FIGURE 4 Change from baseline to week 24 in WPAI+CIQ domain scores. ** p < 0.01; *** p < 0.001. LSM, least‐squares mean; Q4W, every 4 weeks; Q8W, every 8 weeks; SC, subcutaneous; SEM, standard error of the mean; WPAI+CIQ, Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions.
非 KM Figure